Inoviq (ASX: IIQ) — Company Overview, News & Financial Data
Inoviq is a biotechnology company focused on developing and commercializing diagnostic tests and exosome therapeutics for oncology.
Inoviq
Inoviq is a biotechnology company focused on developing and commercializing diagnostic tests and exosome therapeutics for oncology. The company's core technology platforms include exosome capture tools for research and clinical liquid biopsy applications, immunocytochemistry assays for bladder cancer detection, and engineered protein platforms targeting specific cancer biomarkers. Its research pipeline includes liquid biopsy screening tests for early detection of ovarian cancer and preclinical exosome therapeutics for targeted drug delivery. Headquartered in Australia, the business serves clinical laboratories, academic research institutions, and biopharmaceutical partners.
Snapshot
Operations
Products and/or services of Inoviq
- Exosome Isolation Tools: Research products that utilize specialized antibody-coated magnetic beads to isolate and purify exosomes from biological fluids including human plasma, serum, and urine for liquid biopsy research, diagnostic development, and biomarker discovery.
- Bladder Cancer Diagnostic Assays: Immunocytochemistry testing kits used as an adjunct to standard urine cytology for the clinical detection of bladder cancer, assisting cytopathologists in accurately identifying malignant urothelial cells in patient urine samples.
- Glycan Detection Technology Platforms: Engineered recombinant protein platforms designed to selectively bind specific Neu5Gc glycan biomarkers overexpressed on human cancer cells, facilitating enhanced sensitivity in blood-based diagnostic assays, tissue imaging, and therapeutic monitoring applications across multiple solid tumor types.
- Ovarian Cancer Screening Assays: Clinical-stage blood tests in development that capture specific exosome biomarkers to enable early detection of ovarian cancer in asymptomatic or high-risk female patient populations, aiming to improve overall survival rates through timely intervention.
- Exosome Therapeutics Programs: Preclinical drug delivery platforms utilizing engineered extracellular vesicles to package and transport therapeutic payloads, including nucleic acids and targeted small molecules, directly to specific cancer cells to enhance treatment efficacy while minimizing systemic toxicity.
- Breast Cancer Monitoring Diagnostics: Blood-based liquid biopsy assays under development that measure exosome-bound tumor markers to monitor breast cancer progression, evaluate response to ongoing systemic therapies, and detect early disease recurrence in post-treatment patient monitoring.
Inoviq executive team
- Dr. Leearne Maree Hinch B.Sc., B.V.M.S., M.B.A., M.R.C.V.S.Chief Executive Officer
- Mr. Mark Edwards BACC, C.A.CFO & Company Secretary
- Ms. Rebecca LimChief Scientific Officer
- Dr. Emma Ball B.Sc., M.B.A., Ph.D.Chief Commercial Officer